Petros Pharmaceuticals, Inc. (PTPI)
USD 0.25
(-7.78%)
USD 0.25
(-7.78%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 5.82 Million USD | -2.83% |
| 2022 | 5.99 Million USD | -23.29% |
| 2021 | 7.81 Million USD | -18.29% |
| 2020 | 9.55 Million USD | -38.63% |
| 2019 | 15.57 Million USD | 10.86% |
| 2018 | 14.05 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.38 Million USD | 481.28% |
| 2024 Q2 | 1.42 Million USD | 2.35% |
| 2023 Q2 | 1.99 Million USD | -20.81% |
| 2023 Q3 | 1.67 Million USD | -16.02% |
| 2023 FY | 5.82 Million USD | -2.83% |
| 2023 Q4 | -364.25 Thousand USD | -121.75% |
| 2023 Q1 | 2.51 Million USD | 215.5% |
| 2022 FY | 5.99 Million USD | -23.29% |
| 2022 Q4 | 798.1 Thousand USD | 154.75% |
| 2022 Q3 | -1.45 Million USD | -134.82% |
| 2022 Q2 | 4.18 Million USD | 69.83% |
| 2022 Q1 | 2.46 Million USD | 384.28% |
| 2021 FY | 7.81 Million USD | -18.29% |
| 2021 Q4 | -867.16 Thousand USD | -140.42% |
| 2021 Q3 | 2.14 Million USD | -12.71% |
| 2021 Q2 | 2.45 Million USD | -39.7% |
| 2021 Q1 | 4.07 Million USD | 39.13% |
| 2020 FY | 9.55 Million USD | -38.63% |
| 2020 Q4 | 2.92 Million USD | -15.45% |
| 2020 Q3 | 3.46 Million USD | 152.24% |
| 2020 Q2 | 1.37 Million USD | -23.35% |
| 2020 Q1 | 1.79 Million USD | -14.58% |
| 2019 Q1 | 5.08 Million USD | 0.0% |
| 2019 Q4 | 2.09 Million USD | -51.97% |
| 2019 FY | 15.57 Million USD | 10.86% |
| 2019 Q3 | 4.36 Million USD | 8.59% |
| 2019 Q2 | 4.02 Million USD | -20.97% |
| 2018 FY | 14.05 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 98.804% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 88.489% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 98.973% |
| Cosmos Health Inc. | 53.37 Million USD | 89.092% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -440.911% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 94.995% |
| Cronos Group Inc. | 88.84 Million USD | 93.446% |
| Incannex Healthcare Limited | 12 Thousand USD | -48419.9% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 95.461% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 75.833% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 75.833% |
| SCYNEXIS, Inc. | 140.14 Million USD | 95.845% |
| Safety Shot Inc | 202.67 Thousand USD | -2772.842% |
| Theratechnologies Inc. | 81.76 Million USD | 92.879% |
| Alpha Teknova, Inc. | 36.68 Million USD | 84.128% |
| Universe Pharmaceuticals INC | 32.3 Million USD | 81.979% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 99.137% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | 54.28% |
| Dynavax Technologies Corporation | 232.28 Million USD | 97.493% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 98.685% |
| Radius Health, Inc. | 2.88 Billion USD | 99.798% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -201.913% |
| Alvotech | 91.43 Million USD | 93.632% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 98.746% |
| SIGA Technologies, Inc. | 139.91 Million USD | 95.839% |
| Shineco, Inc. | 9.8 Million USD | 40.599% |
| Silver Spike Investment Corp. | 11.72 Million USD | 50.33% |
| Journey Medical Corporation | 79.18 Million USD | 92.647% |
| Embecta Corp. | 1.12 Billion USD | 99.481% |
| Harrow Health, Inc. | 130.19 Million USD | 95.528% |
| Procaps Group, S.A. | 409.92 Million USD | 98.58% |
| Biofrontera Inc. | 34.07 Million USD | 82.911% |
| DURECT Corporation | 8.54 Million USD | 31.886% |
| PainReform Ltd. | - USD | -Infinity% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 99.042% |
| OptiNose, Inc. | 70.98 Million USD | 91.798% |
| RedHill Biopharma Ltd. | 6.51 Million USD | 10.606% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 98.656% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 85.279% |
| ProPhase Labs, Inc. | 44.38 Million USD | 86.882% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 99.428% |
| Procaps Group S.A. | 409.92 Million USD | 98.58% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -347.188% |
| Viatris Inc. | 15.42 Billion USD | 99.962% |
| Rockwell Medical, Inc. | 83.61 Million USD | 93.036% |
| Aytu BioPharma, Inc. | 81 Million USD | 92.812% |
| Tilray Brands, Inc. | 788.94 Million USD | 99.262% |
| PetIQ, Inc. | 1.1 Billion USD | 99.472% |
| Talphera, Inc. | 651 Thousand USD | -794.376% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.691% |
| Alimera Sciences, Inc. | 80.75 Million USD | 92.79% |
| Assertio Holdings, Inc. | 152.06 Million USD | 96.171% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | 79.178% |
| Hempacco Co., Inc. | 4.04 Million USD | -43.918% |
| Alvotech | 91.43 Million USD | 93.632% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 99.551% |
| Kamada Ltd. | 144.75 Million USD | 95.978% |
| Currenc Group, Inc. | 53.25 Million USD | 89.067% |
| Indivior PLC | 1.09 Billion USD | 99.467% |
| Evoke Pharma, Inc. | 5.18 Million USD | -12.388% |
| Flora Growth Corp. | 76.07 Million USD | 92.346% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -440.911% |
| Evolus, Inc. | 202.08 Million USD | 97.119% |
| HUTCHMED (China) Limited | 837.99 Million USD | 99.305% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 99.096% |
| Akanda Corp. | 2.16 Million USD | -169.549% |